{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:04:14Z","timestamp":1794373454586,"version":"4.9.0"},"reference-count":125,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Chronic myelomonocytic leukemia (CMML) is an aggressive clonal stem cell disorder categorized among myelodysplastic\/ myeloproliferative overlap neoplasms. While sharing features with both myelodysplastic syndromes and myeloproliferative neoplasms, CMML has distinct molecular and clinical profiles. The presence of CMML-specific prognostic models, response criteria, and dedicated clinical trials underscores a unique and complex biology. Age-related changes affecting the bone marrow microenvironment, immune responses, and the intricate balance between epigenetic deregulation and proinflammatory signaling are characteristic of this disease, collectively posing significant scientific and clinical challenges in its management. CMML is an aging-related, clinically heterogeneous neoplasm with limited approved therapeutic options, representing an area of unmet medical need. This review offers a comprehensive analysis of the current understanding of the molecular mechanisms driving CMML evolution and its clinical manifestations within the ever-evolving landscape of precision medicine. In light of the most recent molecular discoveries, we highlight the shortcomings of existing therapies and underscore promising investigational agents. Many of the biological findings discussed are shared across a spectrum of acute and chronic myeloid neoplasms, as well as clonal hematopoiesis, broadening the scope of this review.<\/jats:p>","DOI":"10.3324\/haematol.2024.286061","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T03:35:22Z","timestamp":1729136122000},"page":"22-36","source":"Crossref","is-referenced-by-count":15,"title":["Chronic myelomonocytic leukemia: molecular pathogenesis and therapeutic innovations"],"prefix":"10.3324","volume":"110","author":[{"given":"Ludovica","family":"Marando","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford M.","family":"Csizmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"key":"70502","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"70503","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Tefferi A. Atypical chronic myeloid leukemia and myelodysplastic\/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023; 98(4):681-689.","DOI":"10.1002\/ajh.26828"},{"key":"70504","doi-asserted-by":"crossref","unstructured":"Merlevede J, Droin N, Qin T. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nat Commun. 2016; 7:10767.","DOI":"10.1038\/ncomms10767"},{"key":"70505","doi-asserted-by":"crossref","unstructured":"Ball M, List AF, Padron E. When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia. Blood. 2016; 128(20):2381-2387.","DOI":"10.1182\/blood-2016-07-692988"},{"key":"70506","doi-asserted-by":"crossref","unstructured":"Gelsi-Boyer V, Trouplin V, Roquain J. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010; 151(4):365-375.","DOI":"10.1111\/j.1365-2141.2010.08381.x"},{"key":"70507","doi-asserted-by":"crossref","unstructured":"Niyongere S, Lucas N, Zhou JM. Heterogeneous expression of cytokines accounts for clinical diversity and refines prognostication in CMML. Leukemia. 2019; 33(1):205-216.","DOI":"10.1038\/s41375-018-0203-0"},{"key":"70508","doi-asserted-by":"crossref","unstructured":"Mitchell E, Spencer Chapman M, Williams N. Clonal dynamics of haematopoiesis across the human lifespan. Nature. 2022; 606(7913):343-350.","DOI":"10.1038\/s41586-022-04786-y"},{"key":"70509","doi-asserted-by":"crossref","unstructured":"Fabre MA, de Almeida JG, Fiorillo E. The longitudinal dynamics and natural history of clonal haematopoiesis. Nature. 2022; 606(7913):335-342.","DOI":"10.1038\/s41586-022-04785-z"},{"key":"70510","doi-asserted-by":"crossref","unstructured":"Mason CC, Khorashad JS, Tantravahi SK. Age-related mutations and chronic myelomonocytic leukemia. Leukemia. 2016; 30(4):906-913.","DOI":"10.1038\/leu.2015.337"},{"key":"70511","doi-asserted-by":"crossref","unstructured":"Genovese G, K\u00e4hler AK, Handsaker RE. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-2487.","DOI":"10.1056\/NEJMoa1409405"},{"key":"70512","doi-asserted-by":"crossref","unstructured":"Jaiswal S, Fontanillas P, Flannick J. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014; 371(26):2488-2498.","DOI":"10.1056\/NEJMoa1408617"},{"key":"70513","doi-asserted-by":"crossref","unstructured":"Abelson S, Collord G, Ng SWK. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018; 559(7714):400-404.","DOI":"10.1038\/s41586-018-0317-6"},{"key":"70514","doi-asserted-by":"crossref","unstructured":"Kuranda K, Vargaftig J, de la Rochere P. Age-related changes in human hematopoietic stem\/progenitor cells. Aging Cell. 2011; 10(3):542-546.","DOI":"10.1111\/j.1474-9726.2011.00675.x"},{"key":"70515","doi-asserted-by":"crossref","unstructured":"Plowden J, Renshaw-Hoelscher M, Engleman C, Katz J, Sambhara S. Innate immunity in aging: impact on macrophage function. Aging Cell. 2004; 3(4):161-167.","DOI":"10.1111\/j.1474-9728.2004.00102.x"},{"key":"70516","doi-asserted-by":"crossref","unstructured":"Chambers SM, Shaw CA, Gatza C, Fisk CJ, Donehower LA, Goodell MA. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol. 2007; 5(8):e201.","DOI":"10.1371\/journal.pbio.0050201"},{"key":"70517","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Lasho TL, Vijayvargiya P. Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia. Blood Cancer J. 2016; 6(1)","DOI":"10.1038\/bcj.2015.113"},{"key":"70518","doi-asserted-by":"crossref","unstructured":"Mei M, Pillai R, Kim S. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023; 108(1):150-160.","DOI":"10.3324\/haematol.2021.280203"},{"key":"70519","doi-asserted-by":"crossref","unstructured":"Itzykson R, Kosmider O, Renneville A. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013; 31(19):2428-2436.","DOI":"10.1200\/JCO.2012.47.3314"},{"key":"70520","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Itzykson R, Lasho TL. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients. Leukemia. 2014; 28(11):2206-2212.","DOI":"10.1038\/leu.2014.125"},{"key":"70521","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Parikh SA, Hanson CA, Tefferi A. Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review. Br J Haematol. 2014; 165(3):273-286.","DOI":"10.1111\/bjh.12756"},{"key":"70522","doi-asserted-by":"crossref","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L. Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013; 122(22):3616-3627.","DOI":"10.1182\/blood-2013-08-518886"},{"key":"70523","doi-asserted-by":"crossref","unstructured":"Palomo L, Meggendorfer M, Hutter S. Molecular landscape and clonal architecture of adult myelodysplastic\/ myeloproliferative neoplasms. Blood. 2020; 136(16):1851-1862.","DOI":"10.1182\/blood.2019004229"},{"key":"70524","doi-asserted-by":"crossref","unstructured":"Awada H, Nagata Y, Goyal A. Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia. Blood Adv. 2019; 3(3):339-349.","DOI":"10.1182\/bloodadvances.2018024216"},{"key":"70525","doi-asserted-by":"crossref","unstructured":"Rasmussen KD, Jia G, Johansen JV. Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis. Genes Dev. 2015; 29(9):910-922.","DOI":"10.1101\/gad.260174.115"},{"key":"70526","doi-asserted-by":"crossref","unstructured":"Ito K, Lee J, Chrysanthou S. Non-catalytic roles of Tet2 are essential to regulate hematopoietic stem and progenitor cell homeostasis. Cell Rep. 2019; 28(10):2480-2490.e4.","DOI":"10.1016\/j.celrep.2019.07.094"},{"key":"70527","doi-asserted-by":"crossref","unstructured":"Li Z, Cai X, Cai CL. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood. 2011; 118(17):4509-4518.","DOI":"10.1182\/blood-2010-12-325241"},{"key":"70528","doi-asserted-by":"crossref","unstructured":"Ostrander EL, Kramer AC, Mallaney C. Divergent effects of Dnmt3a and Tet2 mutations on hematopoietic progenitor cell fitness. Stem Cell Rep. 2020; 14(4):551-560.","DOI":"10.1016\/j.stemcr.2020.02.011"},{"key":"70529","doi-asserted-by":"crossref","unstructured":"Jakobsen NA, Turkalj S, Zeng AGX. Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging. Cell Stem Cell. 2024; 31(8):1127-1144.","DOI":"10.1016\/j.stem.2024.05.010"},{"key":"70530","doi-asserted-by":"crossref","unstructured":"Zhang J, Lieu YK, Ali AM. Disease-associated mutation in SRSF2 misregulates splicing by altering RNA-binding affinities. Proc Natl Acad Sci U S A. 2015; 112(34):E4726-4734.","DOI":"10.1073\/pnas.1514105112"},{"key":"70531","doi-asserted-by":"crossref","unstructured":"Kim E, Ilagan JO, Liang Y. SRSF2 mutations contribute to myelodysplasia by mutant-specific effects on exon recognition. Cancer Cell. 2015; 27(5):617-630.","DOI":"10.1016\/j.ccell.2015.04.006"},{"key":"70532","doi-asserted-by":"crossref","unstructured":"Kon A, Yamazaki S, Nannya Y. Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice. Blood. 2018; 131(6):621-635.","DOI":"10.1182\/blood-2017-01-762393"},{"key":"70533","doi-asserted-by":"crossref","unstructured":"Smeets MF, Tan SY Xu JJ. Srsf2P95H initiates myeloid bias and myelodysplastic\/myeloproliferative syndrome from hemopoietic stem cells. Blood. 2018; 132(6):608-621.","DOI":"10.1182\/blood-2018-04-845602"},{"key":"70534","doi-asserted-by":"crossref","unstructured":"Gelsi-Boyer V, Trouplin V, Ad\u00e9la\u00efde J. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol. 2009; 145(6):788-800.","DOI":"10.1111\/j.1365-2141.2009.07697.x"},{"key":"70535","doi-asserted-by":"crossref","unstructured":"Abdel-Wahab O, Adli M, LaFave LM. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012; 22(2):180-193.","DOI":"10.1016\/j.ccr.2012.06.032"},{"key":"70536","doi-asserted-by":"crossref","unstructured":"Asada S, Goyama S, Inoue D. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis. Nat Commun. 2018; 9(1):2733.","DOI":"10.1038\/s41467-018-05085-9"},{"key":"70537","doi-asserted-by":"crossref","unstructured":"Campagne A, Lee MK, Zielinski D. BAP1 complex promotes transcription by opposing PRC1-mediated H2A ubiquitylation. Nat Commun. 2019; 10(1):348.","DOI":"10.1038\/s41467-018-08255-x"},{"key":"70538","doi-asserted-by":"crossref","unstructured":"Binder M, Carr RM, Lasho TL. Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. Nat Commun. 2022; 13(1):1434.","DOI":"10.1038\/s41467-022-29142-6"},{"key":"70539","doi-asserted-by":"crossref","unstructured":"Carr RM, Vorobyev D, Lasho T. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021; 12(1):2901.","DOI":"10.1038\/s41467-021-23186-w"},{"key":"70540","doi-asserted-by":"crossref","unstructured":"Bezerra ED, Lasho TL, Finke CM. CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer J. 2021; 11(3):54.","DOI":"10.1038\/s41408-021-00449-9"},{"key":"70541","doi-asserted-by":"crossref","unstructured":"Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci U S A. 2014; 111(7):2548-2553.","DOI":"10.1073\/pnas.1324297111"},{"key":"70542","doi-asserted-by":"crossref","unstructured":"Shlush LI, Zandi S, Mitchell A. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014; 506(7488):328-333.","DOI":"10.1038\/nature13038"},{"key":"70543","doi-asserted-by":"crossref","unstructured":"Lasho T, Patnaik MM. Juvenile myelomonocytic leukemia - a bona fide RASopathy syndrome. Best Pract Res Clin Haematol. 2020; 33(2):101171.","DOI":"10.1016\/j.beha.2020.101171"},{"key":"70544","doi-asserted-by":"crossref","unstructured":"Li Q, Bohin N, Wen T. Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. Nature. 2013; 504(7478):143-147.","DOI":"10.1038\/nature12830"},{"key":"70545","doi-asserted-by":"crossref","unstructured":"H\u00e9rault A, Binnewies M, Leong S. Myeloid progenitor cluster formation drives emergency and leukaemic myelopoiesis. Nature. 2017; 544(7648):53-58.","DOI":"10.1038\/nature21693"},{"key":"70546","doi-asserted-by":"crossref","unstructured":"Ferrall-Fairbanks MC, Dhawan A, Johnson B. Progenitor hierarchy of chronic myelomonocytic leukemia identifies inflammatory monocytic-biased trajectory linked to worse outcomes. Blood Cancer Discov. 2022; 3(6):536-553.","DOI":"10.1158\/2643-3230.BCD-21-0217"},{"key":"70547","doi-asserted-by":"crossref","unstructured":"Hamarsheh S, Osswald L, Saller BS. Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. Nat Commun. 2020; 11(1):1659.","DOI":"10.1038\/s41467-020-15497-1"},{"key":"70548","doi-asserted-by":"crossref","unstructured":"Hurtado-Navarro L, Cuenca-Zamora EJ, Zamora L. NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy. Cell Rep Med. 2023; 4(12):101329.","DOI":"10.1016\/j.xcrm.2023.101329"},{"key":"70549","doi-asserted-by":"crossref","unstructured":"Broz P, Pelegr\u00edn P, Shao F. The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2020; 20(3):143-157.","DOI":"10.1038\/s41577-019-0228-2"},{"key":"70550","doi-asserted-by":"crossref","unstructured":"Baroja-Mazo A, Mart\u00edn-S\u00e1nchez F, Gomez AI. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014; 15(8):738-748.","DOI":"10.1038\/ni.2919"},{"key":"70551","doi-asserted-by":"crossref","unstructured":"Franklin BS, Bossaller L, De Nardo D. The adaptor ASC has extracellular and \u2018prionoid\u2019 activities that propagate inflammation. Nat Immunol. 2014; 15(8):727-737.","DOI":"10.1038\/ni.2913"},{"key":"70552","doi-asserted-by":"crossref","unstructured":"Schmid MC, Avraamides CJ, Dippold HC. Receptor tyrosine kinases and TLR\/IL1Rs unexpectedly activate myeloid cell PI3kg, a single convergent point promoting tumor inflammation and progression. Cancer Cell. 2011; 19(6):715-727.","DOI":"10.1016\/j.ccr.2011.04.016"},{"key":"70553","doi-asserted-by":"crossref","unstructured":"Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged?. Nat Rev Drug Discov. 2020; 19(8):533-552.","DOI":"10.1038\/s41573-020-0068-6"},{"key":"70554","doi-asserted-by":"crossref","unstructured":"You X, Liu F, Binder M. Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation. Blood. 2022; 139(7):1066-1079.","DOI":"10.1182\/blood.2021012519"},{"key":"70555","doi-asserted-by":"crossref","unstructured":"Lucas N, Duchmann M, Rameau P. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019; 33(10):2466-2480.","DOI":"10.1038\/s41375-019-0447-3"},{"key":"70556","doi-asserted-by":"crossref","unstructured":"Mangaonkar AA, Reichard KK, Binder M. Bone marrow dendritic cell aggregates associate with systemic immune dysregulation in chronic myelomonocytic leukemia. Blood Adv. 2020; 4(21):5425-5430.","DOI":"10.1182\/bloodadvances.2020002415"},{"key":"70557","doi-asserted-by":"crossref","unstructured":"Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016; 37(3):193-207.","DOI":"10.1016\/j.it.2016.01.002"},{"key":"70558","doi-asserted-by":"crossref","unstructured":"Munn DH, Zhou M, Attwood JT. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science. 1998; 281(5380):1191-1193.","DOI":"10.1126\/science.281.5380.1191"},{"key":"70559","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Pophali PA, Lasho TL. Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation. Haematologica. 2019; 104(6):e236-e239.","DOI":"10.3324\/haematol.2018.208082"},{"key":"70560","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Timm MM, Vallapureddy R. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J. 2017; 7(7):e584.","DOI":"10.1038\/bcj.2017.66"},{"key":"70561","doi-asserted-by":"crossref","unstructured":"Padron E, Painter JS, Kunigal S. GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. Blood. 2013; 121(25):5068-5077.","DOI":"10.1182\/blood-2012-10-460170"},{"key":"70562","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Sallman DA, Mangaonkar AA. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020; 136(7):909-913.","DOI":"10.1182\/blood.2019004352"},{"key":"70563","doi-asserted-by":"crossref","unstructured":"Hiwase D, Ross DM, Steven W. Lenzilumab in addition to azacitidine improves complete response rates in chronic myelomonocytic leukemia. Blood. 2023; 142(Supplement 1):1847.","DOI":"10.1182\/blood-2023-179688"},{"key":"70564","doi-asserted-by":"crossref","unstructured":"Watanabe S, Itoh T, Arai K. Roles of JAK kinases in human GM-CSF receptor signal transduction. J Allergy Clin Immunol. 1996; 98(6 Pt 2):S183-191.","DOI":"10.1016\/S0091-6749(96)70065-9"},{"key":"70565","doi-asserted-by":"crossref","unstructured":"Padron E, Dezern A, Andrade-Campos M. Myelodysplastic Syndrome Clinical Research Consortium. A multi-institution phase I trial of ruxolitinib in patients with chronic myelomonocytic leukemia (CMML). Clin Cancer Res. 2016; 22(15):3746-3754.","DOI":"10.1158\/1078-0432.CCR-15-2781"},{"key":"70566","doi-asserted-by":"crossref","unstructured":"Selimoglu-Buet D, Wagner-Ballon O, Saada V. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015; 125(23):3618-3626.","DOI":"10.1182\/blood-2015-01-620781"},{"key":"70567","doi-asserted-by":"crossref","unstructured":"Franzini A, Pomicter AD, Yan D. The transcriptome of CMML monocytes is highly inflammatory and reflects leukemiaspecific and age-related alterations. Blood Adv. 2019; 3(20):2949-2961.","DOI":"10.1182\/bloodadvances.2019000585"},{"key":"70568","doi-asserted-by":"crossref","unstructured":"Elb\u00e6k MV, S\u00f8rensen AL, Hasselbalch HC. Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis?. Ann Hematol. 2019; 98(1):101-109.","DOI":"10.1007\/s00277-018-3489-0"},{"key":"70569","doi-asserted-by":"crossref","unstructured":"Mekinian A, Grignano E, Braun T. Systemic inflammatory and autoimmune manifestations associated with myelodysplastic syndromes and chronic myelomonocytic leukaemia: a French multicentre retrospective study. Rheumatology (Oxford). 2016; 55(2):291-300.","DOI":"10.1093\/rheumatology\/kev294"},{"key":"70570","doi-asserted-by":"crossref","unstructured":"Papo M, Diamond EL, Cohen-Aubart F. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017; 130(8):1007-1013.","DOI":"10.1182\/blood-2017-01-761718"},{"key":"70571","doi-asserted-by":"crossref","unstructured":"Bonnet P, Chasset F, Moguelet P. Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation. Haematologica. 2019; 104(11):e530-e533.","DOI":"10.3324\/haematol.2019.223552"},{"key":"70572","doi-asserted-by":"crossref","unstructured":"Ghobadi A, Miller CA, Li T. Shared cell of origin in a patient with Erdheim-Chester disease and acute myeloid leukemia. Haematologica. 2019; 104(8):e373-e375.","DOI":"10.3324\/haematol.2019.217794"},{"key":"70573","doi-asserted-by":"crossref","unstructured":"Pietras EM, Mirantes-Barbeito C, Fong S. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat Cell Biol. 2016; 18(6):607-618.","DOI":"10.1038\/ncb3346"},{"key":"70574","doi-asserted-by":"crossref","unstructured":"Meisel M, Hinterleitner R, Pacis A. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature. 2018; 557(7706):580-584.","DOI":"10.1038\/s41586-018-0125-z"},{"key":"70575","doi-asserted-by":"crossref","unstructured":"Zhang Q, Zhao K, Shen Q. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature. 2015; 525(7569):389-393.","DOI":"10.1038\/nature15252"},{"key":"70576","doi-asserted-by":"crossref","unstructured":"Cull AH, Snetsinger B, Buckstein R, Wells RA, Rauh MJ. Tet2 restrains inflammatory gene expression in macrophages. Exp Hematol. 2017; 55:56-70.","DOI":"10.1016\/j.exphem.2017.08.001"},{"key":"70577","doi-asserted-by":"crossref","unstructured":"Abegunde SO, Buckstein R, Wells RA, Rauh MJ. An inflammatory environment containing TNFa favors Tet2-mutant clonal hematopoiesis. Exp Hematol. 2018; 59:60-65.","DOI":"10.1016\/j.exphem.2017.11.002"},{"key":"70578","doi-asserted-by":"crossref","unstructured":"Cai Z, Kotzin JJ, Ramdas B. Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell. 2018; 23(6):833-849.","DOI":"10.1016\/j.stem.2018.10.013"},{"key":"70579","doi-asserted-by":"crossref","unstructured":"Lee SC, North K, Kim E. Synthetic lethal and convergent biological effects of cancer-associated spliceosomal gene mutations. Cancer Cell. 2018; 34(2):225-241.","DOI":"10.1016\/j.ccell.2018.07.003"},{"key":"70580","doi-asserted-by":"crossref","unstructured":"Smith MA, Choudhary GS, Pellagatti A. U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies. Nat Cell Biol. 2019; 21(5):640-650.","DOI":"10.1038\/s41556-019-0314-5"},{"key":"70581","doi-asserted-by":"crossref","unstructured":"Sevin M, Debeurme F, Laplane L. Cytokine-like protein 1-induced survival of monocytes suggests a combined strategy targeting MCL1 and MAPK in CMML. Blood. 2021; 137(24):3390-3402.","DOI":"10.1182\/blood.2020008729"},{"key":"70582","doi-asserted-by":"crossref","unstructured":"Casta\u00f1o-D\u00edez S, L\u00f3pez-Guerra M, Bosch-Casta\u00f1eda C. Real-world data on chronic myelomonocytic leukemia: clinical and molecular characteristics, treatment, emerging drugs, and patient outcomes. Cancers (Basel). 2022; 14(17):4107.","DOI":"10.3390\/cancers14174107"},{"key":"70583","doi-asserted-by":"crossref","unstructured":"Santini V, Allione B, Zini G. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018; 32(2):413-418.","DOI":"10.1038\/leu.2017.186"},{"key":"70584","doi-asserted-by":"crossref","unstructured":"Coston T, Pophali P, Vallapureddy R. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients. Am J Hematol. 2019; 94(7):767-779.","DOI":"10.1002\/ajh.25488"},{"key":"70585","doi-asserted-by":"crossref","unstructured":"Coltro G, Mangaonkar AA, Lasho TL. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML) - a study of 1084 patients. Leukemia. 2020; 34(5):1407-1421.","DOI":"10.1038\/s41375-019-0690-7"},{"key":"70586","doi-asserted-by":"crossref","unstructured":"Schnegg-Kaufmann AS, Thoms JAI, Bhuyan GS. Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy. Blood. 2023; 141(11):1316-1321.","DOI":"10.1182\/blood.2022018602"},{"key":"70587","doi-asserted-by":"crossref","unstructured":"Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013; 27(7):1441-1450.","DOI":"10.1038\/leu.2013.100"},{"key":"70588","doi-asserted-by":"crossref","unstructured":"Guan Y, Greenberg EF, Hasipek M. Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia. Commun Biol. 2020; 3(1):493.","DOI":"10.1038\/s42003-020-01220-9"},{"key":"70589","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-662.","DOI":"10.1056\/NEJMoa2012971"},{"key":"70590","doi-asserted-by":"crossref","unstructured":"Tremblay D, Csizmar CM, DiNardo CD. Venetoclax (VEN) improves response rates but not survival in patients with chronic myelomonocytic leukemia (CMML) treated with hypomethylating agents (HMA): a multicenter, propensity score analysis. Blood. 2023; 142(Supplement 1):321.","DOI":"10.1182\/blood-2023-181795"},{"key":"70591","doi-asserted-by":"crossref","unstructured":"Pei S, Pollyea DA, Gustafson A. monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia. Cancer Discov. 2020; 10(4):536-551.","DOI":"10.1158\/2159-8290.CD-19-0710"},{"key":"70592","doi-asserted-by":"crossref","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022; 19(10):637-655.","DOI":"10.1038\/s41571-022-00671-9"},{"key":"70593","doi-asserted-by":"crossref","unstructured":"Holderfield M, Lee BJ, Jiang J. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy. Nature. 2024; 629(8013):919-926.","DOI":"10.1038\/s41586-024-07205-6"},{"key":"70594","doi-asserted-by":"crossref","unstructured":"Villaume MT, Arrate MP, Ramsey HE. The delta isoform of phosphatidylinositol-3-kinase predominates in chronic myelomonocytic leukemia and can be targeted effectively with umbralisib and ruxolitinib. Exp Hematol. 2021; 97:57-65.","DOI":"10.1016\/j.exphem.2021.02.008"},{"key":"70595","doi-asserted-by":"crossref","unstructured":"Palii SS, Van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-Aza-2\u2019-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008; 28(2):752-771.","DOI":"10.1128\/MCB.01799-07"},{"key":"70596","doi-asserted-by":"crossref","unstructured":"Th\u00e9pot S, Lainey E, Cluzeau T. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle. 2011; 10(14):2323-2330.","DOI":"10.4161\/cc.10.14.16399"},{"key":"70597","doi-asserted-by":"crossref","unstructured":"Yabushita T, Chinen T, Nishiyama A, Asada S, Shimura R, Isobe T. Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment. Cell Rep. 2023; 42(9):113098.","DOI":"10.1016\/j.celrep.2023.113098"},{"key":"70598","doi-asserted-by":"crossref","unstructured":"Itzykson R, Santini V, Thepot S. Decitabine versus hydroxyurea for advanced proliferative chronic myelomonocytic leukemia: results of a randomized phase III trial within the EMSCO network. J Clin Oncol. 2023; 41(10):1888-1897.","DOI":"10.1200\/JCO.22.00437"},{"key":"70599","doi-asserted-by":"crossref","unstructured":"Kobayashi Y, Munakata W, Ogura M. Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. Int J Hematol. 2018; 107(1):83-91.","DOI":"10.1007\/s12185-017-2327-9"},{"key":"70600","doi-asserted-by":"crossref","unstructured":"Gillberg L, \u00d8rskov AD, Nasif A. Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: normalization of plasma vitamin C induces epigenetic changes. Clin Epigenetics. 2019; 11(1):143.","DOI":"10.1186\/s13148-019-0739-5"},{"key":"70601","doi-asserted-by":"crossref","unstructured":"Xie Z, McCullough K, Lasho TL. Phase II study assessing safety and preliminary efficacy of high dose intravenous ascorbic acid in patients with TET2 mutant clonal cytopenias. Blood. 2023; 142(Supplement 1):4611.","DOI":"10.1182\/blood-2023-186595"},{"key":"70602","doi-asserted-by":"crossref","unstructured":"Yee KW, Chen HW, Hedley DW. A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia. Invest New Drugs. 2016; 34(5):614-624.","DOI":"10.1007\/s10637-016-0375-2"},{"key":"70603","doi-asserted-by":"crossref","unstructured":"Navada SC, Garcia-Manero G, OdchimarReissig R. Rigosertib in combination with azacitidine in patients with myelodysplastic syndromes or acute myeloid leukemia: results of a phase 1 study. Leuk Res. 2020; 94:106369.","DOI":"10.1016\/j.leukres.2020.106369"},{"key":"70604","doi-asserted-by":"crossref","unstructured":"Short NJ, Jabbour E, Naqvi K. A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents. Am J Hematol. 2019; 94(1):74-79.","DOI":"10.1002\/ajh.25318"},{"key":"70605","doi-asserted-by":"crossref","unstructured":"Steensma DP, Wermke M, Klimek VM. Phase I first-inhuman dose escalation study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms. Leukemia. 2021; 35(12):3542-3550.","DOI":"10.1038\/s41375-021-01328-9"},{"key":"70606","doi-asserted-by":"crossref","unstructured":"Assi R, Kantarjian HM, Garcia-Manero G. A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms. Am J Hematol. 2018; 93(2):277-285.","DOI":"10.1002\/ajh.24972"},{"key":"70607","doi-asserted-by":"crossref","unstructured":"Hunter AM, Newman H, Dezern AE. Integrated human and murine clinical study establishes clinical efficacy of ruxolitinib in chronic myelomonocytic leukemia. Clin Cancer Res. 2021; 27(22):6095-6105.","DOI":"10.1158\/1078-0432.CCR-21-0935"},{"key":"70608","doi-asserted-by":"crossref","unstructured":"Padron E, Tinsley-Vance SM, DeZern AE. Efficacy and safety of ruxolitinib for treatment of symptomatic chronic myelomonocytic leukemia (CMML): results of a multicenter phase II clinical trial. Blood. 2022; 140(Supplement 1):1101-1103.","DOI":"10.1182\/blood-2022-170144"},{"key":"70609","doi-asserted-by":"crossref","unstructured":"Borthakur G, Popplewell L, Boyiadzis M. Activity of the oral mitogen-activated protein kinase kinase Inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Cancer. 2016; 122(12):1871-1879.","DOI":"10.1002\/cncr.29986"},{"key":"70610","doi-asserted-by":"crossref","unstructured":"Feldman EJ, Cortes J, DeAngelo DJ. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia. 2008; 22(9):1707-1711.","DOI":"10.1038\/leu.2008.156"},{"key":"70611","doi-asserted-by":"crossref","unstructured":"Ravoet C, Mineur P, Robin V. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study. Ann Hematol. 2008; 87(11):881-885.","DOI":"10.1007\/s00277-008-0536-2"},{"key":"70612","doi-asserted-by":"crossref","unstructured":"Buckstein R, Kerbel R, Cheung M. Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. Leuk Res. 2014; 38(7):756-763.","DOI":"10.1016\/j.leukres.2014.03.022"},{"key":"70613","doi-asserted-by":"crossref","unstructured":"Kenealy M, Patton N, Filshie R. Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML). Leuk Lymphoma. 2017; 58(2):298-307.","DOI":"10.1080\/10428194.2016.1190971"},{"key":"70614","doi-asserted-by":"crossref","unstructured":"Burgstaller S, Stauder R, Kuehr T. A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1. Leuk Lymphoma. 2018; 59(5):1121-1126.","DOI":"10.1080\/10428194.2017.1369070"},{"key":"70615","doi-asserted-by":"crossref","unstructured":"Sekeres MA, Othus M, List AF. Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017; 35(24):2745-2753.","DOI":"10.1200\/JCO.2015.66.2510"},{"key":"70616","doi-asserted-by":"crossref","unstructured":"Ad\u00e8s L, Duployez N, Guerci-Bresler A. A randomised phase II study of azacitidine (AZA) alone or with lenalidomide (LEN), valproic acid (VPA) or idarubicin (IDA) in higher-risk MDS or low blast AML: GFM\u2019s \u201cpick a winner\u201d trial, with the impact of somatic mutations. Br J Haematol. 2022; 198(3):535-544.","DOI":"10.1111\/bjh.18193"},{"key":"70617","doi-asserted-by":"crossref","unstructured":"Attar EC, Amrein PC, Fraser JW. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013; 37(9):1016-1020.","DOI":"10.1016\/j.leukres.2013.05.011"},{"key":"70618","doi-asserted-by":"crossref","unstructured":"Sekeres MA, Watts J, Radinoff A. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-r.isk MDS\/CMML or low-blast AML. Leukemia. 2021; 35(7):2119-2124.","DOI":"10.1038\/s41375-021-01125-4"},{"key":"70619","doi-asserted-by":"crossref","unstructured":"Short NJ, Muftuoglu M, Ong F. A phase 1\/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023; 16(1):73.","DOI":"10.1186\/s13045-023-01476-8"},{"key":"70620","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Ali H, Wang ES. Tagraxofusp (SL-401) in patients with chronic myelomonocytic leukemia (CMML): updated results of an ongoing phase 1\/2 trial. Blood. 2021; 138(Supplement 1):538.","DOI":"10.1182\/blood-2021-147827"},{"key":"70621","doi-asserted-by":"crossref","unstructured":"Patnaik MM, Sallman DA, Mangaonkar AA. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia. Blood. 2020; 136(7):909-913.","DOI":"10.1182\/blood.2019004352"},{"key":"70622","doi-asserted-by":"crossref","unstructured":"Hiwase D, Ross DM, Lane SW. Lenzilumab in addition to azacitidine improves complete response rates in chronic myelomonocytic leukemia. Blood. 2023; 142(Supplement 1):1847.","DOI":"10.1182\/blood-2023-179688"},{"key":"70623","doi-asserted-by":"crossref","unstructured":"Brunner AM, Esteve J, Porkka K. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol. 2024; 99(2):E32-E36.","DOI":"10.1002\/ajh.27161"},{"key":"70624","doi-asserted-by":"crossref","unstructured":"Saliba AN, Litzow MR, Gangat N. Outcomes of venetoclaxbased therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. Am J Hematol. 2021; 96(11):E433-E436.","DOI":"10.1002\/ajh.26334"},{"key":"70625","doi-asserted-by":"crossref","unstructured":"Montalban-Bravo G, Hammond D, DiNardo CD. Activity of venetoclax-based therapy in chronic myelomonocytic leukemia. Leukemia. 2021; 35(5):1494-1499.","DOI":"10.1038\/s41375-021-01240-2"},{"key":"70626","doi-asserted-by":"crossref","unstructured":"Tremblay D, Csizmar CM, DiNardo CD. Venetoclax (VEN) improves response rates but not survival in patients with chronic myelomonocytic leukemia (CMML) treated with hypomethylating agents (HMA): a multicenter, propensity score analysis. Blood. 2023; 142(Supplement 1):321.","DOI":"10.1182\/blood-2023-181795"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286061\/77622","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.286061\/77936","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11790\/77622","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:07:27Z","timestamp":1794046047000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.286061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286061","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,17]]}}}